Drug Profile


Alternative Names: BI 10773/linagliptin FDC (high dose) - Boehringer Ingelheim; Jentadueto; Jentadueto XR; JentaDuo; linagliptin and metformin hydrochloride extended-release; Linagliptin/metformin FDC; Metformin/linagliptin; Trajenta Duo

Latest Information Update: 30 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Eli Lilly
  • Class Alkynes; Antihyperglycaemics; Biguanides; Insulin sensitisers; Piperidines; Purines; Quinazolines; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; CD26 antigen inhibitors; Gluconeogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 15 Dec 2016 Committee for Medicinal Products for Human Use (CHMP) of EMA adopts a positive opinion recommending approval of linagliptin/metformin for extension to an existing indication of Type-2 diabetes mellitus
  • 31 May 2016 Linagliptin/metformin has a boxed warning for lactic acidosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top